Futibatinib

DB15149ApprovedInvestigationalSmall moleculeKinase Inhibitor

Futibatinib is a kinase inhibitor used to treat intrahepatic cholangiocarcinoma in previously treated adults. Futibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and survival.

Chemical structure of Futibatinib
Mechanism
Curator reviewed · 9 references
Primary indication
Futibatinib is indicated to treat adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harbouring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.Curator reviewed · 5 structured indications
Formula / weight
C22H22N6O3 · 418.457 g/mol (avg)
First approval
United States, 2023 · European Union, 2023
Code names
TAS-120
Brand names
  • Lytgobi 20 Mg Daily Dose

Resolves to

Structure
InChIKeyKEIPNCCJPRMIAX-HNNXBMFYSA-NSMILESCOC1=CC(=CC(OC)=C1)C#CC1=NN([C@H]2CCN(C2)C(=O)C=C)C2=C1C(N)=NC=N2

What you can answer from here — as of June 15, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
2TransportersSubstrate / inhibitor direction, not just membership
Listed above
359Drug interactionsStructured to mechanism, not free text
Sign in
25Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
10Marketed productsAcross 3 countries and 2 labellers
Sign in
1ATC codeIncluding every combination product, plus 13 drug categories
Sign in
24+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Futibatinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account